Key trends: pharma’s focus for 2018

Both serialisation and driving down the costs of producing medicines have been hot topics in 2017. Despite the delay of the active enforcement of the US Drug Supply Chain Security Act (DSCSA), companies are still facing an uphill battle to compliance and drug developers and manufacturers are continuing to focus on new ways to reduce time, and by extension costs, to market.

CMOs have a responsibility to their customers and should in fact be a solution to the serialization challenge, especially for those smaller companies that will struggle to comply alone due to the cost and time burdens.


In this roundtable with Pharmaceutical Processing, Mark Quick, VP, Corporate Development, Recipharm, discusses the continued focus on serialisation as we head into 2018, the important role that CMOs play in achieving compliance and the rising pressures to bring drugs to market more quickly.

Read the full roundtable here: The biggest trends in pharma